Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China.

Xiao HanJun GuoXiaoyong TangHui ZhuDongyuan ZhuXiqin ZhangXiangjiao MengYing HuaZhongtang WangYan ZhangWei HuangLinlin WangShuanghu YuanPingliang ZhangHeyi GongYulan SunYingjie ZhangZengjun LiuZhehai Wang

Published in: Journal of cancer research and clinical oncology (2022)

This prospective phase II study in China suggested that sintilimab plus docetaxel might improve PFS and tumor response with good tolerability for Chinese patients with previously treated advanced NSCLC. bTMB reduction at 6 weeks could serve as a potential predictive biomarker for this regimen.

Keyphrases

phase ii study
advanced non small cell lung cancer
locally advanced
open label
epidermal growth factor receptor
rectal cancer
placebo controlled
squamous cell carcinoma
small cell lung cancer
radiation therapy
clinical trial
study protocol
randomized controlled trial
risk assessment
climate change